Where is Vicarious Surgical based?

Vicarious Surgical is based in Waltham, Massachusetts, USA.

When was Vicarious Surgical founded?

Vicarious Surgical was founded in 2014.

What does Vicarious Surgical make?

Vicarious Surgical has 1 robot model on the DEPLOY registry: V1 (Vicarious Surgical builds both physical robots and the AI that runs them).

Where does Vicarious Surgical operate robots?

Vicarious Surgical is a robot manufacturer and does not directly operate deployments on the DEPLOY registry. Its products are deployed by customer operators; see the company page for the verified deployment record.

Is Vicarious Surgical safe?

Vicarious Surgical has no incidents on record in the DEPLOY registry. This does not constitute a safety guarantee; it reflects the incidents DEPLOY has tracked and verified to date.

Vicarious Surgical

Overview

Vicarious Surgical is a US surgical-robotics startup (Waltham, MA; SPAC-listed 2021, NYSE: RBOT) developing the V1 single-port robotic surgery system that uses miniature robots that enter the body through a single incision, miniaturizing surgical robotics.

Verified record

Verified deployments: None on file
Active incidents: None on file

DEPLOY Intelligence

Market intelligence for physical AI

Analyst-grade signals, competitive tracking, and investment context across the global physical AI landscape. Launching 2026.

Models (1)

View all models →

Current platform

V1

Vicarious Surgical (based in the Waltham, Massachusetts area; public via a 2021 SPAC merger as NYSE: RBOT) is developing the V1, a single-port surgical robot concept built around a 9-degree-of-freedom human-like instrument and an immersive virtual-reality-style surgeon interface meant to transport the surgeon inside the patient. The headline finding is the company's distress: its first-quarter 2026 Form 10-Q carries an explicit going-concern substantial-doubt, with cash and short-term investments of $3.682 million as of March 31, 2026 and a stated runway only through the second quarter of 2026, a quarterly net loss of $7.329 million, and zero revenue ever, since the product has never been commercialized; NYSE trading was suspended on March 3, 2026 with delisting proceedings commenced, and the stock moved to the OTCQB on March 24, 2026 after a reverse split used as a survival maneuver. The registry records V1 at research maturity, because it has no FDA clearance and not even an FDA submission yet, with its planned De Novo pathway and first-in-human study repeatedly delayed, so under the verified-vs-claimed framework no clearance means research-tier regardless of years of demonstrations, and the differentiators remain engineering concepts in animal-lab and design-freeze stage. The lifecycle is recorded as active but materially at risk of becoming discontinued within the cash-runway window, and this record should be re-verified within weeks given the Q2-2026 cliff.

surgicalView model →

Relationships

DD8 Holdings Corp.Investor KKhosla VenturesInvestor

Founders (3)

Adam Sachscofounderfounded 2014-01-01no longer at company
Sammy Khalifacofounderfounded 2014-01-01no longer at company
Barry Greenecofounderfounded 2014-01-01no longer at company

Former / Previously (3)

Adam Sachs Co-founder & CEO2014 to 2024secondary-verified
Sammy Khalifa Co-founder & CTO2014 to 2024reported, not verified
Barry Greene Co-founder, Medical Advisor2014 to 2024reported, not verified

Safety record

No incidents on record for Vicarious Surgical.

Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.

Peer companies

Intuitive Surgical2 models
Johnson & Johnson2 models
Stryker2 models
Vantis2 models
Asensus Surgical1 model
Auris Health1 model

Financial state

Reporting basis: sec_10q
Cash runway: 3 months (reported)
Revenue disclosed: $0 (sec_10q)
Lifecycle stage: distressed
Counterparty risk class: high
Going concern: flaggedSubstantial-doubt going-concern: cash/ST investments $3.7M at Mar 31 2026, management states only funds operations through Q2 2026 absent new capital; NYSE delisting notice Mar 3 2026, now OTCQB/OTCID: RBOT.
SEC filing: 8-K

Each numeric field carries its own basis marker. Aggregators report a number; this surface preserves the source class so verification depth travels with the value.

Funding rounds (3)

SPAC (D8 Holdings)2021-10-14
$1.1B(reported)
Investors: D8 Holdings Corp. (lead)
Series B2021-01-01
$28M(reported)
Investors: Khosla Ventures (lead)
Series A2018-01-01
$10M(reported)
Investors: Khosla Ventures (lead)

Sources (3)

Common questions

What is Vicarious Surgical?: Vicarious Surgical is a US surgical-robotics startup (Waltham, MA; SPAC-listed 2021, NYSE: RBOT) developing the V1 single-port robotic surgery system that uses miniature robots that enter the body through a single incision, miniaturizing surgical robotics.
Where is Vicarious Surgical based?: Vicarious Surgical is based in Waltham, Massachusetts, USA.
When was Vicarious Surgical founded?: Vicarious Surgical was founded in 2014.
What does Vicarious Surgical make?: Vicarious Surgical has 1 robot model on the DEPLOY registry: V1 (Vicarious Surgical builds both physical robots and the AI that runs them).
Where does Vicarious Surgical operate robots?: Vicarious Surgical is a robot manufacturer and does not directly operate deployments on the DEPLOY registry. Its products are deployed by customer operators; see the company page for the verified deployment record.
Is Vicarious Surgical safe?: Vicarious Surgical has no incidents on record in the DEPLOY registry. This does not constitute a safety guarantee; it reflects the incidents DEPLOY has tracked and verified to date.

Methodology: Verified · 3 sources (1 primary) · last reviewed 2026-07-03

Verification posture

Verified

High confidence

Review state

Stable

Last reviewed 2026-07-03

Sources by quality tier

1: primary-company-ir; Company IR disclosure
1: secondary-trade-publication; Trade publication
1: unclassified; Unclassified source

The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.

Peer companies

Intuitive Surgical2 models
Johnson & Johnson2 models
Stryker2 models
Vantis2 models
Asensus Surgical1 model
Auris Health1 model

No press coverage on file for Vicarious Surgical yet. Coverage appears here automatically as articles are ingested from our press sources.

Machine-readable surfaces

Markdown mirror: /companies/vicarious-surgical.md
RSS feed: /companies/vicarious-surgical/feed.xml
JSON-LD: embedded in this page’s head
REST API: /v1/companies/9dc45318-fb87-4997-a06d-0b54567c6855
Revision history: /companies/vicarious-surgical/history
Data documentation: /data
Query this programmatically: Deploy MCP

Peer companies

Intuitive Surgical2 models
Johnson & Johnson2 models
Stryker2 models
Vantis2 models
Asensus Surgical1 model
Auris Health1 model

DEPLOY Intelligence Score

9.5/ 100

vs 6 months ago

6-month trend

Peer rankingTop 60% of Surgical

Analysis

Limited public visibility and press coverage relative to peers.

Signal flags

Going concernFunding gap >24mo

Dimension breakdown

Safety Record

50.0LOW

Funding Health

15.8HIGH

IP Activity

5.0LOW

Deployment Scale

0.0LOW

Hiring Signal

0.0LOW

Market Presence

0.0LOW

DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.

Last computed: Jul 3, 2026

Intelligence layer